Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Jun. 30, 2019	Aug. 09, 2019	Dec. 31, 2018
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2019
Document Transition Report	false
Entity File Number	001-35647
Entity Registrant Name	LIFEVANTAGE CORP
Entity Central Index Key	0000849146
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0224471
Entity Address, Address Line One	9785 S Monroe Street
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Sandy
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84070
City Area Code	801
Local Phone Number	432-9000
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	LFVN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 188.2
Entity Common Stock, Shares Outstanding		14,116,377
Documents Incorporated by Reference [Text Block]	Portions of the registrant’s definitive proxy statement to be filed subsequent to the date hereof with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s fiscal year 2020 annual meeting of shareholders are incorporated by reference into Part III of this report. Such definitive proxy statement will be filed with the Commission not later than 120 days after the end of the registrant’s fiscal year ended June 30, 2019.

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Current assets
Cash and cash equivalents	$ 18,824	$ 16,652
Accounts receivable	2,066	2,067
Income tax receivable	1,236	451
Inventory, net	13,753	13,627
Prepaid expenses and other	7,309	6,141
Total current assets	43,188	38,938
Long-term assets
Property and equipment, net	7,131	6,587
Intangible assets, net	983	1,115
Deferred income tax asset	2,693	3,255
Other long-term assets	1,278	1,247
TOTAL ASSETS	55,273	51,142
Current liabilities
Accounts payable	5,180	3,813
Commissions payable	7,916	7,546
Income tax payable	592	39
Other accrued expenses	11,053	10,407
Current portion of long-term debt, net	1,454	2,000
Total current liabilities	26,195	23,805
Long-term debt
Principal amount	0	3,500
Less: unamortized discount and deferred offering costs	0	(88)
Long-term debt, net of unamortized discount and deferred offering costs	0	3,412
Other long-term liabilities	1,879	1,978
Total liabilities	28,074	29,195
Commitments and contingencies — Note 12
Stockholders’ equity
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding	0	0
Common stock — par value $0.0001 per share, 40,000 shares authorized and 14,114 and 14,073 issued and outstanding as of June 30, 2019 and 2018, respectively	1	1
Additional paid-in capital	127,096	124,663
Accumulated deficit	(99,960)	(102,731)
Accumulated other comprehensive income	62	14
Total stockholders’ equity	27,199	21,947
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 55,273	$ 51,142

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	14,114,000	14,073,000
Common stock, shares outstanding (in shares)	14,114,000	14,073,000

Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenue, net	$ 225,958	$ 203,204	$ 199,489
Cost of sales	37,973	34,848	33,456
Gross profit	187,985	168,356	166,033
Operating expenses:
Commissions and incentives	108,620	98,193	96,662
Selling, general and administrative	69,551	59,840	64,922
Total operating expenses	178,171	158,033	161,584
Operating income	9,814	10,323	4,449
Other expense:
Interest expense	(323)	(456)	(570)
Other expense, net	(261)	(319)	(969)
Total other expense	(584)	(775)	(1,539)
Income before income taxes	9,230	9,548	2,910
Income tax expense	(1,801)	(3,787)	(1,302)
Net income	$ 7,429	$ 5,761	$ 1,608
Net income per share:
Basic (dollars per share)	$ 0.53	$ 0.41	$ 0.12
Diluted (dollars per share)	$ 0.50	$ 0.41	$ 0.11
Weighted-average shares outstanding:
Basic (in shares)	14,055	13,992	13,881
Diluted (in shares)	14,980	14,136	14,118
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	$ 48	$ 108	$ (87)
Other comprehensive income (loss), net of tax:	48	108	(87)
Comprehensive income	$ 7,477	$ 5,869	$ 1,521

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balances, shares at Jun. 30, 2016		14,028,000
Beginning balances at Jun. 30, 2016	$ 10,649	$ 14	$ 119,242	$ (108,600)	$ (7)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,315		2,315
Exercise of options and warrants, shares		76,000
Exercise of options and warrants	42		42
Issuance of shares related to restricted stock, shares		166,000
Common stock issued under equity award plans	0
Shares canceled or surrendered as payment of tax withholding (shares)		(38,000)
Shares canceled or surrendered as payment of tax withholding	0
Currency translation adjustment	(87)				(87)
Net income	1,608			1,608
Ending balances, shares at Jun. 30, 2017		14,232,000
Ending balances at Jun. 30, 2017	14,527	$ 14	121,599	(106,992)	(94)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,990		2,990
Exercise of options and warrants, shares		21,000
Exercise of options and warrants	61		61
Issuance of shares related to restricted stock, shares		190,000
Common stock issued under equity award plans	0
Shares canceled or surrendered as payment of tax withholding (shares)		(66,000)
Shares canceled or surrendered as payment of tax withholding	0
Repurchase of company stock, shares		(304,000)
Repurchase of company stock	(1,500)			(1,500)
Change in par value of common stock	0	$ (13)	13
Currency translation adjustment	108				108
Net income	5,761			5,761
Ending balances, shares at Jun. 30, 2018		14,073,000
Ending balances at Jun. 30, 2018	21,947	$ 1	124,663	(102,731)	14
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	4,899		4,899
Exercise of options and warrants, shares		155,000
Exercise of options and warrants	701		701
Issuance of shares related to restricted stock, shares		515,000
Common stock issued under equity award plans	0
Shares canceled or surrendered as payment of tax withholding (shares)		(240,000)
Shares canceled or surrendered as payment of tax withholding	$ (3,167)		(3,167)
Repurchase of company stock, shares	(400,000)	(389,000)
Repurchase of company stock	$ (4,655)			(4,655)
Currency translation adjustment	48				48
Net income	7,429			7,429
Ending balances, shares at Jun. 30, 2019		14,114,000
Ending balances at Jun. 30, 2019	$ 27,199	$ 1	$ 127,096	$ (99,960)	$ 62

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities:
Net income	$ 7,429	$ 5,761	$ 1,608
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,895	1,325	1,643
Stock-based compensation	5,525	3,196	2,647
Amortization of deferred financing fees	6	11	12
Amortization of debt discount	36	21	19
Write-off of intangible assets	0	0	350
Deferred income tax	563	831	(740)
Changes in operating assets and liabilities:
Accounts receivable	14	(730)	160
Income tax receivable	(785)	462	(912)
Inventory, net	(64)	2,953	8,309
Prepaid expenses and deposits	1,029	(993)	3,318
Other long-term assets	7	109	103
Accounts payable	1,369	(1,024)	(6,210)
Income tax payable	552	(175)	(3,132)
Other accrued expenses	545	1,935	135
Other long-term liabilities	(332)	(426)	(713)
Net Cash Provided by Operating Activities	17,789	13,256	6,597
Cash Flows from Investing Activities:
Investments in convertible note receivable	(2,000)	0	0
Purchase of equipment	(2,506)	(4,649)	(1,055)
Net Cash Used in Investing Activities	(4,506)	(4,649)	(1,055)
Cash Flows from Financing Activities:
Payment of deferred financing fees	0	(60)	0
Repurchase of company stock	(4,655)	(1,500)	0
Payment on term loan	(4,000)	(2,000)	(2,000)
Shares canceled or surrendered as payment of tax withholding	(3,167)	0	0
Exercise of options and warrants	701	61	42
Net Cash Used in Financing Activities	(11,121)	(3,499)	(1,958)
Foreign Currency Effect on Cash	10	86	(9)
Increase in Cash and Cash Equivalents	2,172	5,194	3,575
Cash and Cash Equivalents — beginning of period	16,652	11,458	7,883
Cash and Cash Equivalents — end of period	18,824	16,652	11,458
Non Cash Investing and Financing Activities:
Increase in property and equipment/other long-term liabilities	0	0	116
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	227	345	438
Cash paid for income taxes	1,286	2,865	5,496
Common stock shares issued upon cashless warrant exercises	0	0	53
Total cashless exercise price of warrants	0	0	88
Gross warrants underlying cashless exercises	$ 0	$ 0	$ 63

Summary of Significant Accounting Policies

12 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. Certain other prior period balances have also been reclassified to conform to the current period presentation.

Use of Estimates

The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (GAAP). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, share-based compensation, and loss contingencies.

Foreign Currency Translation

A portion of the Company’s business operations occurs outside the United States. The local currency of each of the Company’s subsidiaries is generally its functional currency. All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders’ equity is recorded at historical exchange rates. The resulting foreign currency translation adjustments are recorded as a separate component of stockholders’ equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.

Fair Value of Financial Instruments

Accounting guidance on fair value measurements and disclosures requires disclosures about the fair value for all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about fair value of financial instruments are based on pertinent information available to management as of June 30, 2019 and 2018. Accordingly, the estimates presented in these consolidated financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.

Management has estimated the fair values of cash and cash equivalents, accounts receivable, accounts payable, commissions payable and other accrued expenses to approximate their respective carrying values reported in these consolidated financial statements because of their short maturities.

Cash and Cash Equivalents

The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.

Accounts Receivable

The Company’s accounts receivable for the fiscal years ended June 30, 2019 and 2018 consist primarily of credit card receivables. Based on the Company’s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June 30, 2019 or 2018 is not necessary. No bad debt expense was recorded for the fiscal years ended June 30, 2019, 2018 and 2017.

Inventory

As of June 30, 2019 and 2018, inventory consisted of (in thousands):



	As of June 30,
	2019				2018
Finished goods	$	9,903	72.0	%	$	7,859	57.7	%
Raw materials	3,850		28.0	%	5,768		42.3	%
Total inventory	$	13,753	100.0	%	$	13,627	100.0	%

Inventories are carried and depicted above at the lower of cost or market, using the first-in, first-out method, which includes a reduction in inventory values of $0.2 million and $1.4 million at June 30, 2019 and 2018, respectively, related to obsolete and slow-moving inventory.

Convertible Note Receivable

The Company entered into a convertible promissory note agreement with Gig Economy Group, Inc. ("GEG") pursuant to which the Company agreed to loan to GEG up to an aggregate of $2.0 million in a series of loan installments, evidenced by a convertible promissory note having a maturity date of May 31, 2019 ("Convertible Note"). The Convertible Note accrues interest at a rate of 8% per annum, compounded annually. The principal and unpaid accrued interest of the Convertible Note will either be repaid in cash or converted into shares of equity securities of GEG. On May 17, 2019, the Company and GEG entered into an amendment to the Convertible Note to extend the maturity date to December 31, 2019. In all other respects, the Convertible Note remains unchanged from the original agreement. As of June 30, 2019, the note receivable balance was $2.1 million, including accrued interest, which is included in prepaid expenses and other on the condensed consolidated balance sheet.

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:



	Years
Equipment (includes computer hardware and software)	3 - 5
Furniture and fixtures	5
Vehicles	5

Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.

The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.

Intangible Assets

Intangible assets are stated at cost less accumulated amortization. Definite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset’s carrying value and estimated fair value.

Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Annual impairment tests on intangible assets were completed for the fiscal years ended June 30, 2019 and 2018, resulting in no impairment charges.

Impairment of Long-Lived Assets

Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow. For the fiscal years ended June 30, 2019 and 2018, management has concluded that there are no indications of impairment.

Concentration of Credit Risk

Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents. At June 30, 2019, the Company had $14.6 million in cash accounts at one financial institution and $4.2 million in other financial institutions. As of June 30, 2019 and 2018, and during the years then ended, the Company’s cash balances exceeded federally insured limits.

Commissions and Incentives

Commissions and incentives expenses are the Company’s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent distributors, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent distributors for personal purchases. Commissions paid to independent distributors on personal purchases are considered a sales discount and are reported as a reduction to net revenue.

Shipping and Handling

Shipping and handling costs associated with inbound freight and freight out to customers, including independent distributors, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.

Research and Development Costs

The Company expenses all costs related to research and development activities as incurred. Research and development expenses for the fiscal years ended June 30, 2019, 2018 and 2017 were $1.1 million, $1.2 million and $1.1 million, respectively.

Stock-Based Compensation

The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. For awards with market-based performance conditions, the cost of the awards is recognized as the requisite service is rendered by employees, regardless of when, if ever, the market-based performance conditions are satisfied.

The Black-Scholes option pricing model is used to estimate the fair value of stock options. The determination of the fair value of stock options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options.

The fair value of restricted stock grants is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The fair value of performance restricted stock units that include market-based performance conditions is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield, with further adjustments made to reflect the market conditions that must be satisfied in order for the units to vest by using a Monte-Carlo simulation model. Key assumptions for the Monte-Carlo simulation model include the risk-free rate, expected volatility, expected dividends and the correlation coefficient. The fair value of cash-settled performance-based awards, accounted for as liabilities, is remeasured at the end of each reporting period and is based on the closing market price of the Company’s stock on the last day of the reporting period. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated for new corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.

On December 22, 2017, the President of the United States of America signed tax reform legislation (the “2017 Tax Act”), which includes a broad range of tax reform affecting businesses, including corporate tax rates, business deductions, and international tax regulations. Among these changes, the 2017 Tax Act reduces the corporate tax rate from 35% to 21% effective December 31, 2017. The Company has incorporated all other changes resulting from the 2017 Tax Act in its tax related accounts for the fiscal years ended June 30, 2019 and 2018.

Income Per Share

Basic income per common share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.

For the fiscal years ended June 30, 2019, 2018 and 2017, the effects of approximately 0.2 million, 0.4 million and 0.2 million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock, are not included in the computations as their effect was anti-dilutive.

The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):



	Years ended June 30,
	2019		2018		2017
Numerator:
Net income	$	7,429	$	5,761	$	1,608
Denominator:
Basic weighted-average common shares outstanding	14,055		13,992		13,881
Effect of dilutive securities:
Stock awards and options	925		144		237
Diluted weighted-average common shares outstanding	14,980		14,136		14,118
Net income per share, basic	$	0.53	$	0.41	$	0.12
Net income per share, diluted	$	0.50	$	0.41	$	0.11

Segment Information

The Company operates in a single operating segment by selling products to an international network of independent distributors that operates in an integrated manner from market to market. Commissions and incentives expenses are the Company’s largest expense comprised of the commissions paid to its independent distributors. The Company manages its business primarily by managing its international network of independent distributors. The Company does not use profitability reports on a regional or divisional basis for making business decisions. However, the Company does disaggregate revenue in two geographic regions: the Americas region and the Asia/Pacific & Europe region. See disaggregated revenue in Note 3.

The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):



	June 30,
	2019		2018
United States	$	9,772	$	9,778
Japan	$	955	$	921

New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), and has subsequently issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815), ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (collectively, Topic 606).

Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of Topic 606 is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. This guidance was effective for the Company beginning on July 1, 2018 with the option to adopt using either a full retrospective or a modified retrospective approach. The Company adopted Topic 606 using the modified retrospective approach, under which the cumulative effect of initially applying Topic 606 was recognized as an immaterial adjustment to the opening balance of retained earnings as of July 1, 2018.

The Company evaluated each of its revenue streams and identified similar performance obligations under Topic 606 as compared to previous revenue recognition guidance. During its evaluation, the Company reviewed its loyalty points program and, based on the new guidance, changed the method of accounting from a cost provision method to a deferred revenue method, which resulted in immaterial adjustments to beginning balances upon adoption. During fiscal 2019, the Company

discontinued its loyalty points program, which resulted in an increase in revenue of approximately $0.5 million during the year ended June 30, 2019 from the recognition of deferred revenue related to accrued loyalty points.

There are also considerations related to internal control over financial reporting associated with implementing Topic 606. The Company evaluated its control framework for revenue recognition and identified no material changes needed in response to the new guidance. The Company also evaluated the expanded disclosure requirements under Topic 606 and designed and implemented the appropriate controls over gathering and reporting the information required under Topic 606. See Note 3.

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). For lessees, this standard requires that for all leases not considered to be short term, a company recognize both a right-of-use asset and lease liability on its balance sheet, representing the obligation to make payments and the right to use or control the use of a specified asset for the lease term. This standard is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods. The Company expects the adoption will result in a material increase to the assets and liabilities on the consolidated balance sheet, but does not expect a material impact on the consolidated statements of operations and comprehensive income or consolidated statements of cash flows. The Company plans to adopt the standard in the first quarter of fiscal 2020 using the modified retrospective transition method as of the adoption date. The Company plans to elect the package of practical expedients available under the transition provisions of the new standard, including: not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; not reassessing the initial direct cost for any existing leases; and using hindsight in determining the lease term.

In May 2017, FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The standard provides guidance about which changes to the terms or conditions of a share-based award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. This standard became effective for the Company on July 1, 2018.

Revenue

12 Months Ended

Jun. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenue

Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.

The Company generates the majority of its revenue through product sales to customers. These products include the Protandim^®line of dietary supplements, LifeVantage^® Omega+ and ProBio dietary supplements, the TrueScience^® line of Nrf2-infused skin and hair care products, Petandim^™ for Dogs, Axio^® Smart Energy Drink mixes, and the PhysIQ^™ Smart Weight Management System. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed.

The Company also charges amounts to independent distributors to attend events held by the Company. Tickets to events are sold as standalone items or included within packs. For event tickets sold in packs, the Company allocates a portion of the transaction price to the ticket on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Fee revenue associated with ticket sales is recorded in the month that the event is held, which is when the Company has performed its obligations under the contract.

Deferred Revenue

The Company records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. Deferred revenue is included in accrued expenses in the condensed consolidated balance sheets and includes pre-sell tickets to events and obligations related to the Company’s loyalty points program. The Company pre-sells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized. Historically, the Company has offered a loyalty points program for its customers that allows the customers to earn points from ongoing purchases that can be redeemed for products. As of December 31, 2018, the Company discontinued its

loyalty points program and all revenue previously deferred under the program has been recognized. The Company accounted for these points prior to the discontinuance of the program as a reduction to the transaction price based on estimated usage.

Sales Returns and Allowances

Estimated returns are recorded when product is shipped. Subject to some exceptions based on local regulations, the Company’s return policy is to provide a full refund for product returned within 30 days, if the returned product is unopened or defective. After 30 days, the Company generally does not issue refunds to direct sales customers for returned product. The Company allows terminating independent distributors to return up to 30% of unopened, unexpired product that they have purchased within the prior twelve months for a full refund, less a 10% restocking fee. The Company establishes a refund liability reserve and an asset reserve for its right to recover products based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of June 30, 2019 and 2018, the Company’s return liability reserve, net was $0.4 million and $0.4 million, respectively.

Geographic Information

The Company reports revenue in two geographic regions: the Americas region and the Asia/Pacific & Europe region. The following table presents the Company's revenue disaggregated by these two geographic regions (in thousands):



	Years ended June 30,
	2019		2018		2017
Americas	$	163,236	$	151,609	$	150,841
Asia/Pacific & Europe	62,722		51,595		48,648
Total revenue	$	225,958	$	203,204	$	199,489

Additional information as to the Company’s revenue from operations in the most significant geographical areas is set forth below (in thousands):



	Years ended June 30,
	2019		2018		2017
United States	$	151,966	$	142,452	$	144,842
Japan	$	40,796	$	41,843	$	39,390

Major Products

The Company's revenue is largely attributed to two product lines, Protandim^® and TrueScience^®, which each accounted for more than 10% of total revenue for each of the fiscal years ended June 30, 2018 and 2017. For the fiscal year ended June 30, 2019, Protandim^® was the only product line that accounted for more than 10% of total revenue. On a combined basis, these products represent approximately 78.0%, 76.6% and 77.9% of the Company's total revenue for the fiscal years ended June 30, 2019, 2018 and 2017, respectively. The following table shows revenue by major product line for the fiscal years ended June 30, 2019, 2018 and 2017.



	Years ended June 30,
	2019				2018				2017
Protandim^®product line	$	155,499	68.8	%	$	133,923	65.9	%	$	130,873	65.6	%
TrueScience^®product line	20,881		9.2	%	21,665		10.7	%	24,440		12.3	%
Other	49,578		22.0	%	47,616		23.4	%	44,176		22.1	%
Total	$	225,958	100.0	%	$	203,204	100.0	%	$	199,489	100.0	%

Long-Term Debt	12 Months Ended
Long-Term Debt	Jun. 30, 2019
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt On March 30, 2016, the Company entered into a loan agreement (the "2016 Loan Agreement") to refinance its outstanding debt. In connection with the 2016 Loan Agreement and on the same date, the Company entered into a security agreement (the "Security Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of $10.0 million (the "2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed $2.0 million (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement and the Security Agreement, the "2016 Credit Facility"). The principal amount of the 2016 Term Loan is payable in consecutive quarterly installments in the amount of $0.5 million plus accrued interest beginning with the fiscal quarter ended June 30, 2016. If the Company borrows under the 2016 Revolving Loan, interest will be payable quarterly in arrears on the last day of each fiscal quarter. On May 4, 2018, the Company entered into a loan modification agreement, which amended the 2016 Credit Facility (“Amendment No. 1”). Amendment No. 1 revised the maturity date from March 30, 2019 to March 31, 2021 and increased the fixed interest rate for the term loan from 4.93% to 5.68%. Amendment No. 1 also revised certain financial covenants. The minimum fixed charge coverage ratio (as defined in Amendment No. 1) was revised from a minimum of 1.50 to 1.00 to 1.25 to 1.00, measured on a trailing twelve-month basis, at the end of each fiscal quarter. The minimum working capital was increased from $5.0 million to $8.0 million. The funded debt to EBITDA ratio was replaced with the total liabilities to tangible net worth ratio (as defined in Amendment No. 1) of not greater than 3.00 to 1.00 at the end of each quarter. The minimum tangible net worth measure was removed from the financial covenants. The Company’s obligations under the 2016 Credit Facility, as amended, are secured by a security interest in substantially all of the Company’s assets. Loans outstanding under the 2016 Credit Facility, as amended, may be prepaid in whole or in part at any time without premium or penalty. In addition, if, at any time, the aggregate principal amount outstanding under the 2016 Revolving Loan, as amended, exceeds $2.0 million, the Company must prepay an amount equal to such excess. Any principal amount of the 2016 Term Loan, as amended, which is prepaid or repaid may not be re-borrowed. On February 1, 2019, the Company entered into a loan modification agreement, which amended the 2016 Credit Facility, as amended ("Amendment No. 2"). Under Amendment No. 2, the Company made a principal payment of $2.0 million and increased the revolving loan facility from $2.0 million to $5.0 million. Amendment No. 2 also revised certain financial covenants. The minimum fixed charge coverage ratio (as defined in Amendment No. 2) was revised from a minimum of 1.25 to 1.00 to 1.10 to 1.00, measured on a trailing twelve-month basis, at the end of each fiscal quarter. The minimum working capital was decreased from $8.0 million to $6.0 million. The 2016 Credit Facility, as amended, contains customary covenants, including affirmative and negative covenants that, among other things, restrict the Company's ability to create certain types of liens, incur additional indebtedness, declare or pay dividends on or redeem capital stock, make other payments to holders of equity interests in the Company, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, sell assets or enter into consolidations, mergers or transfers of all or any substantial part of the Company's assets. The 2016 Credit Facility, as amended, also contains various financial covenants that require the Company to maintain a certain consolidated working capital amounts, total liabilities to tangible net worth ratios and fixed charge coverage ratios. Additionally, the 2016 Credit Facility, as amended, contains cross-default provisions, whereby a default under the terms of certain indebtedness or an uncured default of a payment or other material obligation of the Company under a material contract of the Company will cause a default on the remaining indebtedness under the 2016 Credit Facility, as amended. As of June 30, 2019, the Company was in compliance with all applicable covenants under the 2016 Credit Facility, as amended. The Company’s book value for the 2016 Credit Facility, as amended, approximates the fair value. The Company will repay the remaining $1.5 million balance of the 2016 Term Loan during fiscal 2020 in accordance with the terms of the 2016 Credit Facility, as amended.

Share-Based Compensation

12 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

Long-Term Incentive Plans

Equity-Settled Plans

The Company adopted, and the shareholders approved, the 2007 Long-Term Incentive Plan (the “2007 Plan”), effective November 21, 2006, to provide incentives to certain eligible employees, directors and consultants. A maximum of 1.4 million shares of the Company’s common stock can be issued under the 2007 Plan in connection with the grant of awards. Awards to purchase common stock have been granted pursuant to the 2007 Plan and are outstanding to various employees, officers, directors, Scientific Advisory Board members and independent distributors at prices between $1.75 and $10.50 per share, with initial vesting periods of one to three years. Awards expire in accordance with the terms of each award and the shares subject to the award are added back to the 2007 Plan upon expiration of the award. The contractual term of stock options granted is generally ten years. As of June 30, 2019, there were stock option awards outstanding, net of awards expired, for the purchase in aggregate of 44,000 shares of the Company’s common stock. No new awards can be granted under the 2007 Plan.

The Company adopted, and the shareholders approved, the 2010 Long-Term Incentive Plan (the “2010 Plan”), effective September 27, 2010, as amended on August 21, 2014, to provide incentives to certain eligible employees, directors and consultants. A maximum of 1.0 million shares of the Company’s common stock can be issued under the 2010 Plan in connection with the grant of awards. Awards to purchase common stock have been granted pursuant to the 2010 Plan and are outstanding to various employees, officers and directors. Outstanding stock options awarded under the 2010 Plan have exercise prices between $5.60 and $20.09 per share, and vest over one to four year vesting periods. Awards expire in accordance with the terms of each award. The contractual term of stock options granted is generally ten years. As of June 30, 2019, there were stock option awards outstanding, net of awards expired, for an aggregate of 0.1 million shares of the Company’s common stock. No new awards will be granted under the 2010 Plan and forfeited or terminated shares may be added to the 2017 Plan pool as described below.

The Company adopted, and the shareholders approved, the 2017 Long-Term Incentive Plan (the “2017 Plan”), effective February 16, 2017 to provide incentives to certain eligible employees, directors and consultants. On February 2, 2018 and November 15, 2018, the shareholders approved amendments to the 2017 Plan to increase by 425,000 shares and 715,000 shares, respectively, the number of shares of the Company's common stock that are available for issuance under the 2017 Plan. The maximum number of shares that can be issued under the 2017 Plan is not to exceed 2,265,000 shares, calculated as the sum of (i) 1,790,000 shares and (ii) up to 475,000 shares previously reserved for issuance under the 2010 Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. As of June 30, 2019, a maximum of 2.3 million shares of the Company's common stock can be issued under the 2017 Plan in connection with the grant of awards. Outstanding stock options awarded under the 2017 Plan have exercise prices of $4.44 per share, and vest over a three year vesting period. Awards expire in accordance with the terms of each award and, upon expiration of the award, the shares subject to the award are added back to the 2017 Plan. The contractual term of stock options granted are substantially the same as described above for the 2007 Plan and 2010 Plan. As of June 30, 2019, there were stock option awards outstanding, net of awards expired, for an aggregate of 0.4 million shares of the Company’s common stock.

Cash-Settled Plans

Performance Units

The Company adopted a performance incentive plan effective July 1, 2016 (the "Fiscal 2017 Performance Plan"). The Fiscal 2017 Performance Plan is intended to provide selected employees an opportunity to earn performance-based cash bonuses whose value is based upon the Company’s stock value and to encourage such employees to provide services to the Company and to attract new individuals with outstanding qualifications. The Fiscal 2017 Performance Plan seeks to achieve this purpose by providing for awards in the form of performance share units (the “Units”). No shares will be issued under the Fiscal 2017 Performance Plan. Awards may be settled only with cash and will be paid subsequent to award vesting. The fair value of share-based compensation awards, that include performance shares, are accounted for as liabilities. Vesting for the Units is subject to achievement of both service-based and performance-based vesting requirements. Performance-based vesting occurs in three installments if the Company meets certain performance criteria generally set for each year of a three-year

performance period. The service-based vesting criteria occurs in a single installment at the end of the third fiscal year after the awards are granted if the participant has continuously remained in service from the date of award through the end of the third fiscal year. The fair value of these awards is based on the trading price of the Company's common stock and is remeasured at each reporting period date until settlement. The Company adopted a separate performance incentive plan effective July 1, 2017 (the "Fiscal 2018 Performance Plan"). The Fiscal 2018 Performance Plan includes performance-based and service-based vesting requirements and payment terms that are substantially the same as described above for the Fiscal 2017 Performance Plan.

Phantom Units

During the fiscal year ended June 30, 2018, the Company awarded phantom units to its executive officers and senior management. The vesting date for the phantom units was December 31, 2018, at which time the units would be settled in cash equal to (i) the number of vested units multiplied by (ii) the positive difference (if any) between the value at December 31, 2018 and $4.76, the closing price of the Company's common stock on the start date. The start date is December 29, 2017, the last business day of calendar year 2017. The fair value of these awards is based on the Black Scholes valuation model and is remeasured at each reporting period date until settlement.

Upon vesting of the phantom units, the awards were partially settled in cash and partially settled with the issuance of restricted stock units. The restricted stock units were issued on January 8, 2019 and vest in a single installment after a one-year vesting period, subject to continued service through the vesting date.

Employee Stock Purchase Plan

General. The Company’s 2019 Employee Stock Purchase Plan ("ESPP") was adopted by its board of directors in September 2018 and its stockholders approved it in November 2018. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code.

Share Reserve. The Company has reserved 400,000 shares of its common stock for issuance under the ESPP. As of June 30, 2019, 400,000 shares were available for issuance under the ESPP. The number of shares reserved under the ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit).

Purchase Price. Employees may purchase each share of common stock under the ESPP at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of the six-month offering periods. An employee’s payroll deductions under the ESPP are limited to 15% of the compensation, and up to a maximum of 3,000 shares may be purchased during any offering period. A participant shall not be granted an option under the ESPP if such option would permit the participant’s rights to purchase stock to accrue at a rate exceeding $25,000 fair market value of stock for each calendar year in which such option is outstanding at any time.

Offering Periods. Unless otherwise determined by the compensation committee, the ESPP will be operated through a series of successive six-month offering periods, which will begin each year on March 1 and September 1.

The first offering period under the ESPP began on March 1, 2019. During the fiscal year ended June 30, 2019, no shares of common stock were purchased under the ESPP.

Stock-Based Compensation

In accordance with accounting guidance for stock-based compensation, payments in equity instruments for goods or services are accounted for by the fair value method. For the fiscal years ended June 30, 2019, 2018 and 2017, stock-based compensation of $4.9 million, $3.0 million and $2.3 million, respectively, was reflected as an increase to additional paid in capital and $0.6 million, $0.2 million and $0.7 million, respectively, was reflected as an increase to other accrued expenses, all of which was employee related.

At June 30, 2019, there was $4.9 million of unrecognized compensation cost related to nonvested share-based compensation arrangements under the 2010 and 2017 Plans, based on management's estimate of the shares that will ultimately vest. The Company expects to recognize such costs over a weighted-average period of 1.62 years.

Stock Options

During the fiscal year ended June 30, 2018, the Company awarded stock options ("FY 2018 Stock Options") to its executive officers and senior management. The vesting period for the FY 2018 Stock Options is three years and occurs as follows, subject to continued service through the applicable vesting dates: one-third of the total number of shares awarded vests on January 1, 2019; and one-twelfth of the total number of shares awarded vests on the last day of each fiscal quarter following

January 1, 2019. The fair value of the stock options will be recognized on a straight-line basis over the requisite service period of the awards.

There were no stock option grants during the fiscal years ended June 30, 2019 and June 30, 2017.

The fair value of stock option awards was estimated using the Black-Scholes option-pricing model with the following assumptions and weighted-average fair value:



	June 30, 2018
Weighted-average grant date fair value	$	2.25
Risk-free interest rate	2.3		%
Expected volatility	59.0		%
Expected life (years)	4.7

The following is a summary of stock option activity for the fiscal years ended June 30, 2019, 2018 and 2017:



	Options (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at June 30, 2016	383		$	7.28

Granted	—		$	—
Exercised	(4	)	4.14			$	17
Forfeited	(62	)	12.64
Expired or Canceled	(7	)	2.45
Outstanding at June 30, 2017	310		6.35

Granted	461		$	4.44
Exercised	(21	)	2.96			$	33
Forfeited	(20	)	16.26
Expired or Canceled	—		—
Outstanding at June 30, 2018	730		4.96

Granted	—		$	—
Exercised	(155	)	4.52			$	1,328
Forfeited	(19	)	4.58
Expired or Canceled	(29	)	4.64
Outstanding at June 30, 2019	527		5.12		7.28	$	4,202
Exercisable at June 30, 2019	310		$	5.60	6.37	$	2,351

Restricted Stock Awards

The following is a summary of restricted stock awards granted during the fiscal years ended June 30, 2019, 2018 and 2017:



	Shares (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2016	231		$	6.24

Granted	156		$	5.81
Vested	(88	)	8.31
Forfeited	(22	)	10.70
Nonvested at June 30, 2017	277		4.98
Vested at June 30, 2017	—		—

Granted	190		$	4.57
Vested	(355	)	4.62
Forfeited	(3	)	5.22
Nonvested at June 30, 2018	109		5.43
Vested at June 30, 2018	—		—

Granted	37		$	11.59
Vested	(56	)	5.55
Forfeited	—		—
Nonvested at June 30, 2019	90		7.87
Vested at June 30, 2019	—		$	—

The total vesting date fair value of restricted shares that vested during the fiscal years ended June 30, 2019, 2018 and 2017 was $0.7 million, $1.6 million and $0.7 million, respectively.

Restricted Stock Units

The following is a summary of restricted stock units granted during the fiscal year ended June 30, 2019:



	Number of Units (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2018	—		$	—

Granted	347		$	13.81
Vested	—		—
Forfeited	(7	)	13.51
Nonvested at June 30, 2019	340		13.81
Vested at June 30, 2019	—		—

No restricted stock units were granted or outstanding during the fiscal years ended June 30, 2018 and 2017, respectively, and no restricted stock units vested during the fiscal year ended June 30, 2019.

Performance Restricted Stock Units

During the fiscal year ended June 30, 2019, the Company awarded performance restricted stock units ("FY 2019 Performance Restricted Stock Units") to certain employees (the "FY 2019 Recipients"). Each FY 2019 Performance Restricted Stock Unit represents a contingent right for the FY 2019 Recipients to receive a distribution of shares of common stock of the Company equal to 0% to 200% of the target number of performance restricted stock units subject to the award. The actual number of shares distributed will be based on the Company's achievement of specified financial performance metrics. The performance period for the FY 2019 Performance Restricted Stock Units ended June 30, 2019. The FY 2019 Performance Restricted Stock Units will vest only to the extent the specified financial performance criteria are achieved and subject to the FY 2019 Recipient’s continued service with the Company, as follows: (i) a portion of the earned award will vest on the first anniversary of the grant date and (ii) an additional portion of the earned award will vest thereafter in a series of quarterly

installments. The fair values of the FY 2019 Performance Restricted Stock Units were based on the grant date fair value which is the closing price of the Company's common stock on the date of grant.

No performance restricted stock units were granted during the fiscal year ended June 30, 2018.

During the fiscal year ended June 30, 2017, the Company awarded performance restricted stock units ("FY 2017 Performance Restricted Stock Units") to its executive officers and senior management (the "FY 2017 Recipients"). Vesting for the FY 2017 Performance Stock Units occurs in a single installment and is achieved at the end of the three year performance period if the participant has continuously remained in service from the date of the award through the end of the performance period. Each performance restricted stock unit represents a contingent right for the FY 2017 Recipients to receive, within thirty days after the end of the performance period, a distribution of shares of common stock of the Company equal to 0% to 200% of the target number of performance restricted stock units subject to the award. The actual number of shares distributed will be based on the Company's total stockholder return ("TSR") performance during the relevant performance period, subject to acceleration upon a change in control of the Company. The vesting for 50% of the target performance restricted stock units is based upon the Company's absolute TSR for the performance period as compared to a matrix of fixed numeric values and the vesting for the other 50% of the target performance restricted stock units is based upon the relative comparison of the Company's TSR to the Vanguard Russell 2000 exchange traded fund TSR. The fair value of the performance restricted stock units will be recognized on a straight-line basis over the requisite service period of the awards, regardless of when, if ever, the market-based performance conditions are satisfied.

The fair values of the FY 2017 Performance Restricted Stock Units were estimated using a Monte Carlo simulation model which included the following assumptions in order to reflect the performance conditions that must be satisfied for the share units to vest:



	June 30, 2017
Risk-free interest rate	1.5	%
Dividend yield	—	%
Expected volatility - Company	62.0	%
Expected volatility - peer company	17.1	%
Total measurement period (years)	2.8

The following is a summary of performance restricted stock units granted during the fiscal years ended June 30, 2019, 2018 and 2017:



	Number of Units (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2016	463		$	13.07

Granted	420		$	4.69
Vested	(10	)	10.76
Forfeited	(111	)	12.86
Nonvested at June 30, 2017	762		8.51

Granted	—		$	—
Vested	—		—
Forfeited	(132	)	7.02
Nonvested at June 30, 2018	630		8.82

Granted⁽¹⁾	348		$	12.98
Vested⁽¹⁾	(479	)	13.28
Forfeited	(49	)	4.99
Nonvested at June 30, 2019	450		7.71
Vested at June 30, 2019	—		$	—



⁽¹⁾	^{Includes shares added by performance.}

No performance restricted stock units vested during the fiscal year ended June 30, 2018. The total vesting date fair value of performance restricted stock units that vested during the fiscal years ended June 30, 2019 and June 30, 2017 was $6.3 million and $0.1 million, respectively.

Cash-Settled Performance Units

The following is a summary of cash-settled performance units granted during the fiscal years ended June 30, 2019, 2018 and 2017:



	Number of Units (in thousands)		Weighted Average Grant Date Fair Value
Outstanding at June 30, 2016, nonvested	51

Granted	95		$	13.17
Vested	(25	)	—
Forfeited	(89	)	$	12.43
Outstanding at June 30, 2017, nonvested	32

Granted	87		$	4.65
Vested	(32	)	—
Forfeited	(29	)	$	6.48
Outstanding at June 30, 2018, nonvested	58

Granted	42		$	11.27
Vested	(32	)	—
Forfeited	(18	)	$	9.07
Outstanding at June 30, 2019, nonvested	50

The fair value of vested awards under the cash-settled performance plan for the fiscal years ended June 30, 2019, 2018 and 2017 was $0.4 million, $0.2 million and $0.1 million, respectively. Payments of $0.3 million, $0.2 million and $0.2 million were made to settle vested cash-settled performance units during the fiscal years ended June 30, 2019, 2018 and 2017, respectively.

Cash-Settled Phantom Units

The fair value of phantom unit awards was estimated using the Black-Scholes option-pricing model with the following assumptions and weighted-average fair value as follows:



	June 30, 2018
Weighted-average grant date fair value	$	0.40
Risk-free interest rate	2.1% - 2.3%
Expected volatility	56.2% - 57.0%
Expected life (years)	0.5 - 0.8

The following is a summary of cash-settled phantom units granted during the fiscal years ended June 30, 2019 and 2018:



	Number of Units (in thousands)		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at June 30, 2017, nonvested	—

Granted	170		$	—	$	68
Vested	—		—
Forfeited	—		$	—
Outstanding at June 30, 2018, nonvested	170		0.50		$	273

Granted	—		$	—
Vested	(170	)	—		$	1,619
Forfeited	—		$	—
Outstanding at June 30, 2019, nonvested	—		—

No phantom units were outstanding as of June 30, 2017 and 2016.

Warrants

As of June 30, 2019, the Company had no outstanding warrants.

The following is a summary of the warrant activity for the fiscal years ended June 30, 2019, 2018 and 2017 (in thousands):



	Common Stock Warrants
Outstanding and exercisable, June 30, 2016	80

Issued	—
Canceled	—
Exercised	(80	)
Expired	—
Outstanding and exercisable, June 30, 2017	—

Issued	—
Canceled	—
Exercised	—
Expired	—
Outstanding and exercisable, June 30, 2018	—

Issued	—
Canceled	—
Exercised	—
Expired	—
Outstanding and exercisable, June 30, 2019	—

As of June 30, 2019, 2018 and 2017, the Company had no warrants classified as derivative liabilities.

Income Taxes

12 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

The income tax expense for the fiscal years ended June 30, 2019, 2018 and 2017 consists of the following (in thousands):



	Year ended June 30,
	2019			2018		2017
Income Before Income Taxes:
Domestic	$	6,596		$	8,234	$	1,642
International	2,634			1,315		1,268
	$	9,230		$	9,549	$	2,910
Current Taxes:
Federal	$	222		$	2,413	$	1,324
State	176			407		137
Foreign	833			150		510
Total Current Income Tax Provision	$	1,231		$	2,970	$	1,971
Deferred Taxes:
Federal	$	502		$	377	$	(473	)
State	109			59		(21		)
Foreign	(41		)	381		(175		)
Total Deferred Income Tax Provision	$	570		$	817	$	(669	)
Net Income Tax Provision	$	1,801		$	3,787	$	1,302

The effective income tax rate for the fiscal years ended June 30, 2019, 2018 and 2017 differs from the U.S. Federal statutory income tax rate due to the following:



	Year ended June 30,
	2019		2018		2017
Federal statutory income tax rate	21.0	%	28.0	%	34.0	%
State income taxes, net of federal benefit	3.1	%	2.5	%	5.9	%
Foreign tax rate difference	4.5	%	1.6	%	(4.6	)%
Tax return to provision true-up	(1.1	)%	(7.4	)%	0.6	%
Limit on future stock compensation due to 162(m)	2.6	%	0.0	%	0.0	%
Other differences	(0.1	)%	0.2	%	(2.1	)%
Revalue of deferred for change in federal tax rate	(0.6	)%	14.9	%	0.0	%
Permanent differences:
— stock based compensation	(7.7	)%	0.7	%	4.6	%
— foreign derived intangible income deduction	(0.1	)%	0.0	%	0.0	%
— domestic production activities deduction	0.0	%	(1.5	)%	(3.3	)%
— tax credits	(3.7	)%	(1.3	)%	(0.9	)%
— meals and entertainment	0.7	%	0.9	%	3.4	%
— penalties	0.1	%	0.1	%	1.5	%
— other	1.6	%	0.9	%	4.3	%
Change in valuation allowance	(0.8	)%	0.1	%	1.3	%
Net income tax provision	19.5	%	39.7	%	44.7	%

The components of the deferred tax assets and liabilities as of June 30, 2019 and 2018 are as follows (in thousands):



	June 30,
	2019			2018
Deferred tax assets:
Federal, state, and foreign net operating loss carryovers	$	448		$	574
Stock option compensation	1,262			1,367
Accrued vacation, allowance for returns, bonuses & other	2,672			2,615
Gross deferred tax asset	$	4,382		$	4,556

Deferred tax liabilities:
Patents and trademarks	$	(132	)	$	(145	)
Property & equipment	(1,194		)	(823		)
Other	(104		)	(13		)
Gross deferred tax liabilities	(1,430		)	(981		)
Less: valuation allowance	(259		)	(320		)
Deferred tax assets, net	$	2,693		$	3,255

On December 22, 2017, the President of the United States signed into law an extensive tax reform bill known as the Tax Cuts and Jobs Act of 2017 (the "Tax Act"), which overhauled U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from 35% to 21% (blended rate in year one for fiscal year filers), implementing a territorial tax system, imposing a one time "deemed repatriation" tax on all untaxed offshore earnings, and adding/modifying/deleting several major tax deductions significant to the company. For the fiscal year ending June 30, 2018, the Company was taxed at a blended Federal rate of 28%. For the fiscal year ended June 30, 2019, the Company will be taxed at the new 21% Federal Rate.

In addition, the Tax Act also includes a provision to tax global intangible low-taxed income ("GILTI") of foreign subsidiaries and a base erosion anti-abuse tax ("BEAT") measure that taxes certain payments between a U.S. Corporation and its subsidiaries. For the fiscal year ended June 30, 2019, the Company became subject to these provisions. The Company does not meet the threshold to be subject to BEAT, neither does it make the types of payments subject to BEAT. The Company does have an immaterial GILTI liability due to limitations on foreign tax credits.

The Tax Act also eliminated the Section 199 deduction and created the Foreign Derived Intangible Income Deduction ("FDII"). As opposed to the Section 199 deduction, which rewarded companies for domestic manufacturing activities, the FDII deduction rewards companies for foreign sales. In the past, the Company has significantly benefited from the Section 199 deduction, but does not currently derive as great a benefit from the FDII deduction due to our business activities.

The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. The Company believes the Company has no material uncertain tax positions and do not expect significant changes in within the next twelve months in the amount of unrecognized tax benefits. Accordingly, the Company has not reserved for interest or penalties. The tax years open for examination by the Internal Revenue Service (“IRS”) include returns for fiscal years June 30, 2016 through present and the open tax years by state tax authorities include returns for fiscal years June 30, 2015 through present. In addition, the IRS and state tax authorities may examine NOL’s for any previous years if utilized by the Company.

As of June 30, 2019, the Company had utilized all of its Federal net operating loss (“NOL”) carry-forwards. The net operating losses were to expire by June 30, 2024 and are subject to review by the Internal Revenue Service, and are subject to U.S. Internal Revenue Code Section 382 limitations. As of June 30, 2019, state NOLs were $7.6 million and foreign NOLs were $0.6 million.

The total recognized tax benefit from settlement of stock based awards for the period ending June 30, 2019 was $0.7 million.

The Company conducts its business globally. As a result, the Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions, and are subject to examination for the open tax years of June 30, 2015 through June 30, 2019.

Commitments and Contingencies

12 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Operating Leases

The Company leases its facilities under non-cancelable operating leases, which expire at various dates through 2021. The facilities leases contain renewal options and are subject to cost increases. Future minimum annual payments under non-cancelable operating leases at June 30, 2019 are as follows (in thousands):



Year ending June 30,	Amount
2020	$	2,872
2021	1,140
Total future minimum lease payments	$	4,012

Rent expense totaled $2.7 million, $2.7 million and $2.5 million for the fiscal years ended June 30, 2019, 2018 and 2017, respectively.

Contingencies

The Company accounts for contingent liabilities in accordance with Accounting Standards Codification ("ASC") Topic 450, Contingencies. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of June 30, 2019, and based on the assessment there are no probable loss contingencies requiring accrual or disclosures within its financial statements.

Legal Accruals

In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the Company's normal conduct of business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss

contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact any such losses, damages or remedies may have on the consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors.

Class Action Lawsuit (Smith v. LifeVantage Corp.): On January 24, 2018, a purported class action was filed in the United States District Court for the District of Connecticut, entitled Smith v. LifeVantage Corp., Case No. 3:18-cv-a35 (D. Connecticut filed Jan. 24, 2018). In this action, plaintiff alleged that the Company, its Chief Executive Officer, Chief Sales Officer and Chief Marketing Officer operated a pyramid scheme in violation of a variety of federal and state statutes, including RICO and the Connecticut Unfair Trade Practices Act. On April 16, 2018, the Company filed motions with the court to dismiss the complaint against LifeVantage, dismiss the complaint against the Company's executives, transfer the venue of the case from the State of Connecticut to the State of Utah, and contest class certification. On July 23, 2018, the parties filed a stipulation with the Court agreeing to transfer the case to the Federal District Court for Utah. On September 20, 2018, Plaintiffs filed an amended complaint in Utah. As per the parties stipulated agreement, plaintiff's amended complaint dropped the RICO and Connecticut state law claims and removed the Company's Chief Sales Officer and Chief Marketing Officer as individual defendants (the Chief Executive Officer remains a defendant in the case). However, the amended complaint adds a new antitrust claim, alleging that the Company fraudulently obtained patents for its products and is attempting to use those patents in an anti-competitive manner. LifeVantage filed a Motion to Dismiss the amended complaint on November 5, 2018, Plaintiffs filed a response to LifeVantage’s Motion to Dismiss on December 17, 2018, and LifeVantage filed a reply brief on January 10, 2019. With the matter now being fully briefed, the Court can issue a ruling based on the briefs submitted by the parties or schedule a hearing for oral argument before entering a decision on the motion. The Company has not established a loss contingency accrual for this lawsuit as it believes liability is not probable or estimable, and the Company plans to vigorously defend against this lawsuit. Nonetheless, an unfavorable resolution of this matter could have a material adverse effect on the Company's business, results of operations or financial condition.

Other Matters. In addition to the matters described above, the Company also may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this Annual Report on Form 10-K, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Consolidation

Use of Estimates

Foreign Currency Translation

Fair Value of Financial Instruments

Cash and Cash Equivalents

The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.

Accounts Receivable

Inventory

Inventories are carried and depicted above at the lower of cost or market, using the first-in, first-out method

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:



	Years
Equipment (includes computer hardware and software)	3 - 5
Furniture and fixtures	5
Vehicles	5

Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.

Intangible Assets

Impairment of Long-Lived Assets

Concentration of Credit Risk

Commissions and Incentives

Shipping and Handling

Research and Development Costs

The Company expenses all costs related to research and development activities as incurred.

Stock-Based Compensation

Income Taxes

Income Per Share

Segment Information

New Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Components of inventory

As of June 30, 2019 and 2018, inventory consisted of (in thousands):



	As of June 30,
	2019				2018
Finished goods	$	9,903	72.0	%	$	7,859	57.7	%
Raw materials	3,850		28.0	%	5,768		42.3	%
Total inventory	$	13,753	100.0	%	$	13,627	100.0	%

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:



	Years
Equipment (includes computer hardware and software)	3 - 5
Furniture and fixtures	5
Vehicles	5

Property and equipment, net consist of (in thousands):



	June 30,
	2019			2018
Equipment (includes computer hardware and software)	$	12,625		$	10,504
Furniture and fixtures	1,611			1,592
Leasehold improvements	3,975			3,761
Vehicles	51			51
Accumulated depreciation	(11,131		)	(9,321		)
Total property and equipment, net	$	7,131		$	6,587

Reconciliation of earnings per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share



	Years ended June 30,
	2019		2018		2017
Numerator:
Net income	$	7,429	$	5,761	$	1,608
Denominator:
Basic weighted-average common shares outstanding	14,055		13,992		13,881
Effect of dilutive securities:
Stock awards and options	925		144		237
Diluted weighted-average common shares outstanding	14,980		14,136		14,118
Net income per share, basic	$	0.53	$	0.41	$	0.12
Net income per share, diluted	$	0.50	$	0.41	$	0.11

Long-lived Assets by Geographic Areas

The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):



	June 30,
	2019		2018
United States	$	9,772	$	9,778
Japan	$	955	$	921

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-based Options Fair Value Valuation Assumptions

The fair value of stock option awards was estimated using the Black-Scholes option-pricing model with the following assumptions and weighted-average fair value:



	June 30, 2018
Weighted-average grant date fair value	$	2.25
Risk-free interest rate	2.3		%
Expected volatility	59.0		%
Expected life (years)	4.7

Summary of Stock Option Activity

The following is a summary of stock option activity for the fiscal years ended June 30, 2019, 2018 and 2017:



	Options (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at June 30, 2016	383		$	7.28

Granted	—		$	—
Exercised	(4	)	4.14			$	17
Forfeited	(62	)	12.64
Expired or Canceled	(7	)	2.45
Outstanding at June 30, 2017	310		6.35

Granted	461		$	4.44
Exercised	(21	)	2.96			$	33
Forfeited	(20	)	16.26
Expired or Canceled	—		—
Outstanding at June 30, 2018	730		4.96

Granted	—		$	—
Exercised	(155	)	4.52			$	1,328
Forfeited	(19	)	4.58
Expired or Canceled	(29	)	4.64
Outstanding at June 30, 2019	527		5.12		7.28	$	4,202
Exercisable at June 30, 2019	310		$	5.60	6.37	$	2,351

Schedule of Nonvested Restricted Shares

The following is a summary of restricted stock awards granted during the fiscal years ended June 30, 2019, 2018 and 2017:



	Shares (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2016	231		$	6.24

Granted	156		$	5.81
Vested	(88	)	8.31
Forfeited	(22	)	10.70
Nonvested at June 30, 2017	277		4.98
Vested at June 30, 2017	—		—

Granted	190		$	4.57
Vested	(355	)	4.62
Forfeited	(3	)	5.22
Nonvested at June 30, 2018	109		5.43
Vested at June 30, 2018	—		—

Granted	37		$	11.59
Vested	(56	)	5.55
Forfeited	—		—
Nonvested at June 30, 2019	90		7.87
Vested at June 30, 2019	—		$	—

Share-based Awards Other Than Options Fair Value Valuation Assumptions



	June 30, 2017
Risk-free interest rate	1.5	%
Dividend yield	—	%
Expected volatility - Company	62.0	%
Expected volatility - peer company	17.1	%
Total measurement period (years)	2.8

The fair value of phantom unit awards was estimated using the Black-Scholes option-pricing model with the following assumptions and weighted-average fair value as follows:



	June 30, 2018
Weighted-average grant date fair value	$	0.40
Risk-free interest rate	2.1% - 2.3%
Expected volatility	56.2% - 57.0%
Expected life (years)	0.5 - 0.8

Summary of Nonvested Restricted Stock Units

The following is a summary of performance restricted stock units granted during the fiscal years ended June 30, 2019, 2018 and 2017:



	Number of Units (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2016	463		$	13.07

Granted	420		$	4.69
Vested	(10	)	10.76
Forfeited	(111	)	12.86
Nonvested at June 30, 2017	762		8.51

Granted	—		$	—
Vested	—		—
Forfeited	(132	)	7.02
Nonvested at June 30, 2018	630		8.82

Granted⁽¹⁾	348		$	12.98
Vested⁽¹⁾	(479	)	13.28
Forfeited	(49	)	4.99
Nonvested at June 30, 2019	450		7.71
Vested at June 30, 2019	—		$	—

Schedule of Performance Share Units Activity

The following is a summary of cash-settled performance units granted during the fiscal years ended June 30, 2019, 2018 and 2017:



	Number of Units (in thousands)		Weighted Average Grant Date Fair Value
Outstanding at June 30, 2016, nonvested	51

Granted	95		$	13.17
Vested	(25	)	—
Forfeited	(89	)	$	12.43
Outstanding at June 30, 2017, nonvested	32

Granted	87		$	4.65
Vested	(32	)	—
Forfeited	(29	)	$	6.48
Outstanding at June 30, 2018, nonvested	58

Granted	42		$	11.27
Vested	(32	)	—
Forfeited	(18	)	$	9.07
Outstanding at June 30, 2019, nonvested	50

Summary of Cash-Settled Phantom Units

The following is a summary of cash-settled phantom units granted during the fiscal years ended June 30, 2019 and 2018:



	Number of Units (in thousands)		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at June 30, 2017, nonvested	—

Granted	170		$	—	$	68
Vested	—		—
Forfeited	—		$	—
Outstanding at June 30, 2018, nonvested	170		0.50		$	273

Granted	—		$	—
Vested	(170	)	—		$	1,619
Forfeited	—		$	—
Outstanding at June 30, 2019, nonvested	—		—

Summary of the Warrants Granted

The following is a summary of the warrant activity for the fiscal years ended June 30, 2019, 2018 and 2017 (in thousands):



	Common Stock Warrants
Outstanding and exercisable, June 30, 2016	80

Issued	—
Canceled	—
Exercised	(80	)
Expired	—
Outstanding and exercisable, June 30, 2017	—

Issued	—
Canceled	—
Exercised	—
Expired	—
Outstanding and exercisable, June 30, 2018	—

Issued	—
Canceled	—
Exercised	—
Expired	—
Outstanding and exercisable, June 30, 2019	—

Income Taxes (Tables)

12 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Components of Income Tax Expense

The income tax expense for the fiscal years ended June 30, 2019, 2018 and 2017 consists of the following (in thousands):



	Year ended June 30,
	2019			2018		2017
Income Before Income Taxes:
Domestic	$	6,596		$	8,234	$	1,642
International	2,634			1,315		1,268
	$	9,230		$	9,549	$	2,910
Current Taxes:
Federal	$	222		$	2,413	$	1,324
State	176			407		137
Foreign	833			150		510
Total Current Income Tax Provision	$	1,231		$	2,970	$	1,971
Deferred Taxes:
Federal	$	502		$	377	$	(473	)
State	109			59		(21		)
Foreign	(41		)	381		(175		)
Total Deferred Income Tax Provision	$	570		$	817	$	(669	)
Net Income Tax Provision	$	1,801		$	3,787	$	1,302

The Effective Income Tax Rate Differs from the U.S. Federal Statutory Income Tax Rate

The effective income tax rate for the fiscal years ended June 30, 2019, 2018 and 2017 differs from the U.S. Federal statutory income tax rate due to the following:



	Year ended June 30,
	2019		2018		2017
Federal statutory income tax rate	21.0	%	28.0	%	34.0	%
State income taxes, net of federal benefit	3.1	%	2.5	%	5.9	%
Foreign tax rate difference	4.5	%	1.6	%	(4.6	)%
Tax return to provision true-up	(1.1	)%	(7.4	)%	0.6	%
Limit on future stock compensation due to 162(m)	2.6	%	0.0	%	0.0	%
Other differences	(0.1	)%	0.2	%	(2.1	)%
Revalue of deferred for change in federal tax rate	(0.6	)%	14.9	%	0.0	%
Permanent differences:
— stock based compensation	(7.7	)%	0.7	%	4.6	%
— foreign derived intangible income deduction	(0.1	)%	0.0	%	0.0	%
— domestic production activities deduction	0.0	%	(1.5	)%	(3.3	)%
— tax credits	(3.7	)%	(1.3	)%	(0.9	)%
— meals and entertainment	0.7	%	0.9	%	3.4	%
— penalties	0.1	%	0.1	%	1.5	%
— other	1.6	%	0.9	%	4.3	%
Change in valuation allowance	(0.8	)%	0.1	%	1.3	%
Net income tax provision	19.5	%	39.7	%	44.7	%

The Components of the Deferred Tax Assets and Liabilities

The components of the deferred tax assets and liabilities as of June 30, 2019 and 2018 are as follows (in thousands):



	June 30,
	2019			2018
Deferred tax assets:
Federal, state, and foreign net operating loss carryovers	$	448		$	574
Stock option compensation	1,262			1,367
Accrued vacation, allowance for returns, bonuses & other	2,672			2,615
Gross deferred tax asset	$	4,382		$	4,556

Deferred tax liabilities:
Patents and trademarks	$	(132	)	$	(145	)
Property & equipment	(1,194		)	(823		)
Other	(104		)	(13		)
Gross deferred tax liabilities	(1,430		)	(981		)
Less: valuation allowance	(259		)	(320		)
Deferred tax assets, net	$	2,693		$	3,255

Summary of Significant Accounting Policies - Narrative (Details)	12 Months Ended
	Jun. 30, 2019 USD ($) Segment	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)
Summary of Significant Accounting Policies Additional Information [Abstract]
Recorded bad debt expense	$ 0	$ 0	$ 0
Aggregate amount that can be loaned	$ 2,000,000.0
Interest rate	8.00%
Note receivable balance	$ 2,100,000
Impairment of intangible assets	0	0
Research and development	$ 1,100,000	$ 1,200,000	$ 1,100,000
Number of geographic segments \| Segment	2
Increase in revenue from recognition of deferred revenue	$ 500,000
Cash Accounts Held Primarily At Financial Institution
Summary of Significant Accounting Policies Additional Information [Abstract]
Concentration of credit risk	14,600,000
Cash Accounts Held at Other Financial Institutions
Summary of Significant Accounting Policies Additional Information [Abstract]
Concentration of credit risk	$ 4,200,000

Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Components of Inventory
Finished goods	$ 9,903	$ 7,859
Raw materials	3,850	5,768
Total inventory	$ 13,753	$ 13,627
Finished goods, percent of inventory	72.00%	57.70%
Raw materials, percent of inventory	28.00%	42.30%
Inventory valuation reserves	$ 200	$ 1,400

Summary of Significant Accounting Policies - Reconciliation of Net Income per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Accounting Policies [Abstract]
Number of antidilutive securities (in shares)									200	400	200
Numerator:
Net income	$ 3,907	$ 1,782	$ 829	$ 911	$ 2,992	$ 1,635	$ 317	$ 817	$ 7,429	$ 5,761	$ 1,608
Denominator:
Basic weighted-average common shares outstanding (in shares)									14,055	13,992	13,881
Effect of dilutive securities:
Stock awards and options (in shares)									925	144	237
Diluted weighted-average common shares outstanding (in shares)									14,980	14,136	14,118
Income per share, basic (dollars per share)	$ 0.27	$ 0.13	$ 0.06	$ 0.07	$ 0.20	$ 0.12	$ 0.02	$ 0.06	$ 0.53	$ 0.41	$ 0.12
Income per share, diluted (dollars per share)	$ 0.26	$ 0.12	$ 0.06	$ 0.06	$ 0.21	$ 0.12	$ 0.02	$ 0.06	$ 0.50	$ 0.41	$ 0.11

Revenue - Narrative (Details) $ in Millions	12 Months Ended
Revenue - Narrative (Details) $ in Millions	Jun. 30, 2019 USD ($) Segment product_line	Jun. 30, 2018 USD ($)	Jun. 30, 2017
Revenue from External Customer [Line Items]
Percentage of products that can be returned for a full refund by terminated distributors	30.00%
Percent of restocking fee	10.00%
Number of geographic segments \| Segment	2
Number of product lines \| product_line	2
Concentration risk, percentage	100.00%	100.00%	100.00%
Return liability \| $	$ 0.4	$ 0.4
Product Concentration Risk \| Revenue Benchmark \| Protandim and TrueScience Product Line
Revenue from External Customer [Line Items]
Concentration risk, percentage	78.00%	76.60%	77.90%

Revenue - Major Products (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
Revenue - Major Products (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Revenue from External Customer [Line Items]
Revenue, net	$ 56,170	$ 56,012	$ 58,167	$ 55,609	$ 54,033	$ 50,562	$ 49,482	$ 49,127	$ 225,958	$ 203,204	$ 199,489
Concentration risk, percentage									100.00%	100.00%	100.00%
Protandim® product line
Revenue from External Customer [Line Items]
Revenue, net									$ 155,499	$ 133,923	$ 130,873
Concentration risk, percentage									68.80%	65.90%	65.60%
TrueScience® product line
Revenue from External Customer [Line Items]
Revenue, net									$ 20,881	$ 21,665	$ 24,440
Concentration risk, percentage									9.20%	10.70%	12.30%
Product and Service, Other [Member]
Revenue from External Customer [Line Items]
Revenue, net									$ 49,578	$ 47,616	$ 44,176
Concentration risk, percentage									22.00%	23.40%	22.10%

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ (11,131)	$ (9,321)
Total property and equipment, net	7,131	6,587
Depreciation expense	1,800	1,200	$ 1,500
Equipment (includes computer hardware and software)
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,625	10,504
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,611	1,592
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,975	3,761
Vehicles
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 51	$ 51

Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, net	$ 983	$ 1,115
Amortization of intangible assets	$ 100	100	$ 100
Definite-lived intangible assets weighted-average amortization period	5 years 9 months
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2020	$ 100
2021	100
2022	100
2023	100
2024	100
Patent costs
Finite-Lived Intangible Assets [Line Items]
Patent costs	2,330	2,330
Accumulated amortization	(1,592)	(1,460)
Total definite-lived intangible assets, net	738	870
Trademark costs
Finite-Lived Intangible Assets [Line Items]
Trademarks and other indefinite-lived intangible assets	$ 245	$ 245

Other Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Payables and Accruals [Abstract]
Accrued incentive compensation	$ 5,726	$ 2,868
Other taxes payable	1,733	1,884
Total other accrued expenses	1,617	2,087
Deferred revenue	998	1,107
Accrued payroll and other employee expenses	791	1,095
Accrued incentives and promotions to distributors	188	1,366
Total other accrued expenses	$ 11,053	$ 10,407

Long-Term Debt (Details)		12 Months Ended
Long-Term Debt (Details)	Feb. 01, 2019 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	May 04, 2018 USD ($)	Mar. 30, 2016 USD ($)
Line of Credit Facility [Line Items]
Principal payment		$ 4,000,000	$ 2,000,000	$ 2,000,000
March 2016 Term Loan \| Secured Debt
Line of Credit Facility [Line Items]
Maximum borrowing capacity						$ 10,000,000.0
Frequency of periodic payment		quarterly
Periodic principal payment		$ 500,000
Fixed interest rate					5.68%	4.93%
Fixed charge coverage ratio	1.10				1.25	1.50
Minimum working capital	$ 6,000,000.0				$ 8,000,000.0	$ 5,000,000.0
Total liabilities to tangible net worth ratio					3.00
Remaining amount to be paid in 2020		$ 1,500,000
March 2016 Revolving Loan \| Secured Debt
Line of Credit Facility [Line Items]
Principal payment	2,000,000.0
March 2016 Revolving Loan \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 5,000,000.0					$ 2,000,000.0

Stockholders' Equity (Details) - USD ($)	12 Months Ended
Stockholders' Equity (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Feb. 01, 2019	Nov. 27, 2017
Class of Stock [Line Items]
Repurchase common stock amount authorized				$ 15,000,000	$ 5,000,000
Stock repurchased during period (in shares)	400,000
Payments for repurchase of common stock	$ 4,655,000	$ 1,500,000	$ 0
Remaining authorized amount of common stock repurchase program	$ 8,800,000
Common Stock
Class of Stock [Line Items]
Common stock issued (in shares)	155,000	21,000	76,000
Restricted common stock to employees (in shares)	515,000	190,000	166,000
Shares canceled or surrendered as payment of tax withholding (shares)	(240,000)	(66,000)	(38,000)
Stock repurchased during period (in shares)	389,000	304,000

Share-Based Compensation - Equity-Settled Plans, Narrative (Details) - $ / shares					12 Months Ended
	Nov. 15, 2018	Feb. 02, 2018	Sep. 27, 2010	Nov. 21, 2006	Jun. 30, 2019
2007 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum common stock issued under Long-Term Incentive Plan (in shares)				1,400,000
Contractual term of stock options granted				10 years
Number of shares of common stock subject for purchase					44,000
2007 Long-Term Incentive Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Right to purchase common stock, minimum price (dollars per share)				$ 1.75
Vesting period				1 year
2007 Long-Term Incentive Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Right to purchase common stock, minimum price (dollars per share)				$ 10.50
Vesting period				3 years
2010 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum common stock issued under Long-Term Incentive Plan (in shares)		475,000	1,000,000.0
Contractual term of stock options granted			10 years
Company's common stock purchased in aggregate (in shares)					100,000
2010 Long-Term Incentive Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Right to purchase common stock, minimum price (dollars per share)			$ 5.60
Vesting period			1 year
2010 Long-Term Incentive Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Right to purchase common stock, minimum price (dollars per share)			$ 20.09
Vesting period			4 years
2017 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum common stock issued under Long-Term Incentive Plan (in shares)		2,265,000			2,300,000
Exercise price of outstanding stock options (dollars per share)					$ 4.44
Vesting period					3 years
Company's common stock purchased in aggregate (in shares)					400,000
Number of additional shares authorized	715,000	425,000
2017 Long Term Incentive Plan Excluding 2010 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum common stock issued under Long-Term Incentive Plan (in shares)		1,790,000

Share-Based Compensation - Employee Stock Purchase Plan, Narrative (Details)	12 Months Ended
	Jun. 30, 2019 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased under the ESPP	0
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock subject for purchase	400,000
Number of shares available for issuance	400,000
Purchase price of stock fair market value	85.00%
Maximum percentage of employee compensation	15.00%
Maximum number of shares that can be purchased during any offering period	3,000
Amount in excess of fair market value of stock for option not to be granted \| $	$ 25,000
Offering period	6 months

Share-Based Compensation - Stock-Based Compensation, Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 4,899	$ 2,990	$ 2,315
Stock-based compensation awards classified as a liability settled in cash	600	$ 200	$ 700
Restricted Stock \| 2010 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 4,900
Period for recognition of unrecognized compensation cost	1 year 7 months 13 days

Share-Based Compensation - Stock Options, Narrative (Details) - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0		0
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Options granted (in shares)	0	461,000	0
Vesting on January 1, 2019 \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting right percentage		33.33%
Vesting on the last day of each fiscal quarter following January 1, 2019 \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting right percentage		8.33%

Share-Based Compensation - Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (dollars per share)		$ 2.25
Risk-free interest rate		2.30%
Expected volatility - Company (as a percent)		59.00%
Total measurement period (years)		4 years 8 months 12 days
Performance Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (dollars per share)	$ 12.98	$ 0	$ 4.69
Risk-free interest rate			1.50%
Dividend yield (as a percent)			0.00%
Expected volatility - Company (as a percent)			62.00%
Expected volatility - peer company (as a percent)			17.10%
Total measurement period (years)			2 years 9 months 18 days
Phantom Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (dollars per share)		$ 0.40
Minimum \| Phantom Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		2.10%
Expected volatility - Company (as a percent)		56.20%
Total measurement period (years)		6 months
Maximum \| Phantom Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		2.30%
Expected volatility - Company (as a percent)		57.00%
Total measurement period (years)		9 months 18 days

Share-Based Compensation - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Summary of Stock Option Activity (shares)
Options, Granted (in shares)	0		0
Employee Stock Option
Summary of Stock Option Activity (shares)
Options, Outstanding beginning balance (in shares)	730,000	310,000	383,000
Options, Granted (in shares)	0	461,000	0
Options, Exercised (in shares)	(155,000)	(21,000)	(4,000)
Options, Forfeited (in shares)	(19,000)	(20,000)	(62,000)
Options, Expired or canceled (in shares)	(29,000)	0	(7,000)
Options, Outstanding ending balance (in shares)	527,000	730,000	310,000
Weighted Average Exercise Price (dollars per share)
Weighted average exercise price, Outstanding beginning balance (dollars per share)	$ 4.96	$ 6.35	$ 7.28
Weighted average exercise price, Granted (dollars per share)	0	4.44	0
Weighted average exercise price, Exercised (dollars per share)	4.52	2.96	4.14
Weighted average exercise price, Forfeited (dollars per share)	4.58	16.26	12.64
Weighted average exercise price, Expired or canceled (dollars per share)	4.64	0	2.45
Weighted average exercise price, Outstanding ending balance (dollars per share)	$ 5.12	$ 4.96	$ 6.35
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term, Outstanding	7 years 3 months 10 days
Additional Disclosures
Options, Exercisable (shares)	310,000
Weighted average exercise price, Exercisable (dollars per share)	$ 5.60
Weighted average remaining contractual term, Exercisable	6 years 4 months 13 days
Aggregate intrinsic value, Exercised	$ 1,328	$ 33	$ 17
Aggregate intrinsic value, Outstanding ending balance	4,202
Aggregate intrinsic value, Exercisable	$ 2,351

Share-Based Compensation - Restricted Shares (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares outstanding beginning period (in shares)	109,000	277,000	231,000
Shares granted (in shares)	37,000	190,000	156,000
Shares vested (in shares)	(56,000)	(355,000)	(88,000)
Shares forfeited (in shares)	0	(3,000)	(22,000)
Shares outstanding ending period (in shares)	90,000	109,000	277,000
Vested shares (in shares)	0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, beginning period (dollars per share)	$ 5.43	$ 4.98	$ 6.24
Weighted average grant date fair value, granted (dollars per share)	11.59	4.57	5.81
Weighted average grant date fair value, vested and issued (dollars per share)	5.55	4.62	8.31
Weighted average grant date fair value, forfeited (dollars per share)	0	5.22	10.70
Weighted average grant date fair value, ending period (dollars per share)	7.87	5.43	4.98
Weighted average granted date fair value, vested shares (dollars per share)	$ 0	$ 0	$ 0
Fair value of vested awards	$ 0.7	$ 1.6	$ 0.7
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares granted (in shares)	347,000	0	0
Shares vested (in shares)	0
Shares forfeited (in shares)	(7,000)
Shares outstanding ending period (in shares)	340,000
Vested shares (in shares)	0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, granted (dollars per share)	$ 13.81
Weighted average grant date fair value, vested and issued (dollars per share)	0
Weighted average grant date fair value, forfeited (dollars per share)	13.51
Weighted average grant date fair value, ending period (dollars per share)	13.81
Weighted average granted date fair value, vested shares (dollars per share)	$ 0	$ 0

Share-Based Compensation - Restricted Stock, Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested awards	$ 0.7	$ 1.6	$ 0.7
Shares granted (in shares)	37,000	190,000	156,000
Outstanding shares (in shares)	0	0	0
Shares vested (in shares)	56,000	355,000	88,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	347,000	0	0
Outstanding shares (in shares)	0	0	0
Shares vested (in shares)	0

Share-Based Compensation - Performance Restricted Stock Units, Narrative (Details) - Performance Restricted Stock Units - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	348,000	0	420,000
Vesting period		3 years	3 years
Distribution period following performance period			30 days
Shares vested (in shares)	479,000	0	10,000
Fair value of vested awards	$ 6.3		$ 0.1
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Distribution percentage of target number of Performance Stock Units			0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Distribution percentage of target number of Performance Stock Units			200.00%
Company's TSR Compared to a Matrix
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting right percentage			50.00%
Company's TSR Compared to Vanguard Russell 2000 Exchange Trade Fund
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting right percentage			50.00%

Share-Based Compensation - Performance Restricted Stock Units (Details) - Performance Restricted Stock Units - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares outstanding beginning period (in shares)	630,000	762,000	463,000
Shares granted (in shares)	348,000	0	420,000
Shares vested (in shares)	(479,000)	0	(10,000)
Shares forfeited (in shares)	(49,000)	(132,000)	(111,000)
Shares outstanding ending period (in shares)	450,000	630,000	762,000
Vested shares (in shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, beginning period (dollars per share)	$ 8.82	$ 8.51	$ 13.07
Weighted average grant date fair value, granted (dollars per share)	12.98	0	4.69
Weighted average grant date fair value, vested and issued (dollars per share)	13.28	0	10.76
Weighted average grant date fair value, forfeited (dollars per share)	4.99	7.02	12.86
Weighted average grant date fair value, ending period (dollars per share)	7.71	$ 8.82	$ 8.51
Weighted average granted date fair value, vested shares (dollars per share)	$ 0
Fair value of vested awards	$ 6.3		$ 0.1

Share-Based Compensation - Cash-Settled Performance Units (Details) - Cash-Settled Performance Units - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares outstanding beginning period (in shares)	58	32	51
Shares granted (in shares)	42	87	95
Shares vested (in shares)	(32)	(32)	(25)
Shares forfeited (in shares)	(18)	(29)	(89)
Shares outstanding ending period (in shares)	50	58	32
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, granted (dollars per share)	$ 11.27	$ 4.65	$ 13.17
Weighted average grant date fair value, vested and issued (dollars per share)	0	0	0
Weighted average grant date fair value, forfeited (dollars per share)	$ 9.07	$ 6.48	$ 12.43
Fair value of vested awards	$ 0.4	$ 0.2	$ 0.1
Payments made to settle vested performance share units	$ 0.3	$ 0.2	$ 0.2

Share-Based Compensation - Cash-Settled Phantom Units (Details) - Phantom Units - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares outstanding beginning period (in shares)	170,000	0	0
Shares granted (in shares)	0	170,000
Shares vested (in shares)	(170,000)	0
Shares forfeited (in shares)	0	0
Shares outstanding ending period (in shares)	0	170,000	0
Weighted average remaining contractual term, Outstanding		6 months
Aggregate intrinsic value, Outstanding ending balance		$ 273
Aggregate intrinsic value, Granted		68
Aggregate intrinsic value, Vested		$ 1,619

Share-Based Compensation - Summary of Warrants (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Payment Arrangement [Abstract]
Outstanding warrants (in shares)	0
Warrants
Summary of the warrants issued
Outstanding and exercisable, Beginning balance (in shares)	0	0	80,000
Issued (in shares)	0	0	0
Canceled (in shares)	0	0	0
Exercised (in shares)	0	0	(80,000)
Expired (in shares)	0	0	0
Outstanding and exercisable, Ending balance (in shares)	0	0	0
Warrants - Derivative Liability
Summary of the warrants issued
Warrants classified as derivative liabilities	$ 0	$ 0	$ 0

Other Expense, Net (Details) - USD ($) $ in Thousands	12 Months Ended
Other Expense, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Other Income and Expenses [Abstract]
Foreign currency transaction loss, net	$ (121)	$ (92)	$ (182)
Loss on settlement of forward contract	(287)	(175)	(292)
Loss on disposal of fixed assets	0	(6)	(12)
Write-off of intangible assets	0	0	(350)
Other income (expense), net	147	(46)	(133)
Total other expense, net	$ (261)	$ (319)	$ (969)

Income Taxes - Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Before Income Taxes:
Domestic	$ 6,596	$ 8,234	$ 1,642
International	2,634	1,315	1,268
Income Before Income Taxes	9,230	9,549	2,910
Current Taxes:
Federal	222	2,413	1,324
State	176	407	137
Foreign	833	150	510
Total Current Income Tax Provision	1,231	2,970	1,971
Deferred Taxes:
Federal	502	377	(473)
State	109	59	(21)
Foreign	(41)	381	(175)
Total Deferred Income Tax Provision	570	817	(669)
Net Income Tax Provision	$ 1,801	$ 3,787	$ 1,302

Income Taxes - Effective Income Tax Rate (Details)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Details)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
The effective income tax rate differs from the U.S. Federal statutory income tax rate
Federal statutory income tax rate	21.00%	28.00%	34.00%
State income taxes, net of federal benefit	3.10%	2.50%	5.90%
Foreign tax rate difference	4.50%	1.60%	(4.60%)
Tax return to provision true-up	(1.10%)	(7.40%)	0.60%
Limit on future stock compensation due to 162(m)	2.60%	0.00%	0.00%
Other differences	(0.10%)	0.20%	(2.10%)
Revalue of deferred for change in federal tax rate	(0.60%)	14.90%	0.00%
Permanent differences:
— stock based compensation	(7.70%)	0.70%	4.60%
— foreign derived intangible income deduction	(0.10%)	(0.00%)	(0.00%)
— domestic production activities deduction	(0.00%)	(1.50%)	(3.30%)
— tax credits	(3.70%)	(1.30%)	(0.90%)
— meals and entertainment	0.70%	0.90%	3.40%
— penalties	0.10%	0.10%	1.50%
— other	1.60%	0.90%	4.30%
Change in valuation allowance	(0.80%)	0.10%	1.30%
Net income tax provision	19.50%	39.70%	44.70%

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Deferred tax assets:
Federal, state, and foreign net operating loss carryovers	$ 448	$ 574
Stock option compensation	1,262	1,367
Accrued vacation, allowance for returns, bonuses & other	2,672	2,615
Gross deferred tax asset	4,382	4,556
Deferred tax liabilities:
Patents and trademarks	(132)	(145)
Property & equipment	(1,194)	(823)
Other	(104)	(13)
Gross deferred tax liabilities	(1,430)	(981)
Less: valuation allowance	(259)	(320)
Deferred tax assets, net	$ 2,693	$ 3,255

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Future minimum lease payments under the non-cancelable leases
2020	$ 2,872
2021	1,140
Total future minimum lease payments	4,012
Rent expense	$ 2,700	$ 2,700	$ 2,500

Interim Financial Results (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Summary of selected quarterly financial information
Revenue, net	$ 56,170	$ 56,012	$ 58,167	$ 55,609	$ 54,033	$ 50,562	$ 49,482	$ 49,127	$ 225,958	$ 203,204	$ 199,489
Gross profit	46,460	46,742	48,373	46,410	45,962	41,641	40,365	40,388	187,985	168,356	166,033
Net income	$ 3,907	$ 1,782	$ 829	$ 911	$ 2,992	$ 1,635	$ 317	$ 817	$ 7,429	$ 5,761	$ 1,608
Per common share:
Income per share, basic (dollars per share)	$ 0.27	$ 0.13	$ 0.06	$ 0.07	$ 0.20	$ 0.12	$ 0.02	$ 0.06	$ 0.53	$ 0.41	$ 0.12
Income per share, diluted (dollars per share)	$ 0.26	$ 0.12	$ 0.06	$ 0.06	$ 0.21	$ 0.12	$ 0.02	$ 0.06	$ 0.50	$ 0.41	$ 0.11

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (3,000)
AOCI Attributable to Parent [Member]
Stockholders' Equity Attributable to Parent	us-gaap_StockholdersEquity	14,000
Additional Paid-in Capital [Member]
Stockholders' Equity Attributable to Parent	us-gaap_StockholdersEquity	124,663,000
Common Stock [Member]
Stockholders' Equity Attributable to Parent	us-gaap_StockholdersEquity	$ 1,000
Shares, Issued	us-gaap_SharesIssued	14,073,000
Retained Earnings [Member]
Stockholders' Equity Attributable to Parent	us-gaap_StockholdersEquity	$ (102,734,000)
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (3,000)

The Company	12 Months Ended
The Company	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	The Company LifeVantage Corporation (the "Company") is a company focused on biohacking the aging code through nutrigenomics, the study of how nutrition and naturally occurring compounds affect our genes. The Company is dedicated to helping people achieve their health, wellness and financial goals. The Company provides quality, scientifically-validated products and a financially rewarding direct sales opportunity to customers and independent distributors. LifeVantage sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland and Belgium. The Company also sells its products in a number of countries to customers for personal consumption only. In addition, the Company sells its products in China through its e-commerce business model. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including Protandim^®, its line of scientifically-validated dietary supplements, LifeVantage^®Omega+ and ProBio dietary supplements, TrueScience^®, its line of skin and hair care products, Petandim™ for Dogs, its companion pet supplement formulated to combat oxidative stress in dogs, Axio^® Smart Energy Drink mixes, and PhysIQ^™, its Smart Weight Management System. The Company was incorporated in Colorado in June 1988 under the name Andraplex Corporation. The Company changed its corporate name to Yaak River Resources, Inc. in January 1992, and subsequently changed it again in October 2004 to Lifeline Therapeutics, Inc. In October 2004 and March 2005, the Company acquired all of the outstanding common stock of Lifeline Nutraceuticals Corporation. In November 2006, the Company changed its name to LifeVantage Corporation. On March 9, 2018, following approval by the Company's stockholders and its 2018 Annual Meeting of Stockholders, the Company changed its state of incorporation from the State of Colorado to the State of Delaware pursuant to a plan of conversion. All outstanding shares of common stock, options and share units of the Colorado corporation were converted into an equivalent share, option or share unit of the Delaware corporation and the par value of the Company's common stock was adjusted to $0.0001. All directors and officers of the Colorado corporation held the same position within the Delaware corporation on the date of reincorporation.

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity During the fiscal years ended June 30, 2019, 2018 and 2017, the Company issued 0.2 million, 21,000 and 0.1 million shares, respectively, of common stock as a result of the exercise of options and warrants. During the fiscal years ended June 30, 2019, 2018 and 2017, the Company issued 0.5 million, 0.2 million and 0.2 million shares, respectively, under the Company's equity incentive plans. During the fiscal years ended June 30, 2019, 2018 and 2017, 0.2 million, 0.1 million and 38,000 shares, respectively of restricted stock were canceled or surrendered as payment of tax withholding upon vesting. On November 27, 2017, the Company announced a share repurchase program authorizing it to repurchase up to $5 million in shares of the Company's common stock. The repurchase program permits the Company to purchase shares through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the Company's management. As part of the repurchase program, the Company has entered into a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan will be completed in accordance with the terms of the plan, including specified price, volume and timing conditions. The authorization may be suspended or discontinued at any time and expires on November 27, 2020. On February 1, 2019, the board of directors approved an amendment to the share repurchase program to increase the authorized share repurchase amount from $5 million to $15 million. During year ended June 30, 2019, the Company purchased 0.4 million shares of its common stock on the open market at an aggregate purchase price of $4.7 million under this repurchase program. At June 30, 2019, there is $8.8 million remaining under this repurchase program. The Company’s Certificate of Incorporation authorizes the designation and issuance shares of preferred stock. However, as of June 30, 2019, none have been issued nor have any rights or preferences been assigned to the preferred stock by the Company’s board of directors.

Related Party Transactions	12 Months Ended
Related Party Transactions	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions During the fiscal year ended June 30, 2018, the Company contracted with GEG for outsourced software application development services pursuant to an agreement entered into between the Company and GEG, which included a convertible note. For discussion related to the convertible note between the Company and GEG, see Note 2. David Toole, who served as a member of the Company's board of directors until February 2, 2018, is a majority owner and an officer of GEG. Additionally, two members of the Company's board of directors serve on the GEG board of directors.

Share-Based Compensation - Cash-Settled Plans, Narrative (Details)		12 Months Ended
	Jan. 08, 2019	Jun. 30, 2019 Vesting_Installlment	Dec. 29, 2017 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (dollars per share) \| $ / shares			$ 4.76
2014 Performance Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vesting installments \| Vesting_Installlment		3
Vesting period		3 years
2014 Performance Incentive Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

Income Taxes - Narrative (Details) $ in Millions	12 Months Ended
Income Taxes - Narrative (Details) $ in Millions	Jun. 30, 2019 USD ($)
Operating Loss Carryforwards [Line Items]
Tax benefit from settlement of stock based awards	$ 0.7
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	7.6
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 0.6

Summary of Significant Accounting Policies - Segment Information (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 9,772	$ 9,778
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 955	$ 921

Share-Based Compensation - Cash-Settled Phantom Units, Narrative (Details) - shares	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Phantom Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of units outstanding (in shares)	0	170,000	0	0